LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") is pleased to announce that its Chief Scientific and Clinical Advisor, Professor Eric Chung, will present pivotal SPONTAN® clinical trial data at the Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting in Perth, from 1 to 4 March 2025.
Highlights
-
470% Faster Absorption: SPONTAN achieves mean maximum plasma concentration in 12 minutes, compared to 56 minutes for oral ED tablets.
-
Lower Dose & Same Efficacy: SPONTAN delivers results with half of the drug dose, maintaining comparable bioavailability and a favourable safety profile.
-
Clinical Validation: These results highlight SPONTAN’s potential to disrupt the global erectile dysfunction (ED) market.
-
Key Prescribers: LTR Pharma will exhibit at USANZ, alongside Restorative Health Clinic, an early adopter of SPONTAN under the TGA’s Special Access Scheme.
LTR Pharma Chief Scientific and Clinical Advisor, Professor Eric Chung, said: "The clinical data underpinning SPONTAN's development demonstrates its potential to address significant unmet needs in erectile dysfunction treatment. The rapid onset of action, coupled with excellent bioavailability and safety profile, offers patients a more spontaneous therapeutic option. This has been further validated through real-world patient feedback under the TGA's Special Access Scheme and Authorised Prescriber pathways. I look forward to sharing these compelling results with my colleagues at USANZ.”
About SPONTAN®
SPONTAN is a nasal spray treatment for erectile dysfunction (ED) that utilises intranasal delivery of a PDE5 inhibitor. The highly vascular nature of the nasal cavity allows for rapid drug absorption, enabling onset within 10 minutes or less. This breakthrough treatment provides greater control over timing, spontaneity, and enjoyment of sexual experiences.
USANZ Conference & Speaker Profile
Professor Eric Chung is a globally recognised expert in Men’s Health and Urology, holding leadership roles in:
-
President-elect, International Society of Sexual Medicine (ISSM)
-
Past Chair, Andrology Section of USANZ
-
Consultant Urological Surgeon, AndroUrology Centre for Male Sexual, Urinary, and Reproductive Excellence
LTR Pharma’s participation at USANZ 2025 underscores its commitment to advancing medical innovation in ED treatment and engaging with leading healthcare professionals.
About us:
About LTR Pharma
LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma’s lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]